A SEER Database Analysis of Urethral Cancer Management
C. Zhang,S. Wang,I. Deutsch
DOI: https://doi.org/10.1016/j.ijrobp.2012.07.1124
IF: 8.013
2012-01-01
International Journal of Radiation Oncology*Biology*Physics
Abstract:Purpose/Objective(s)Urethral cancer comprises less than 1% of malignancies. Large series are not available to inform best practices. Our analysis was conducted with the intent of providing additional information about this disease.Materials/MethodsPatients with urethral cancer diagnosed between 1973 and 2008 were identified in the Surveillance, Epidemiology and End Results (SEER) database. The influences of demographic characteristics and treatment modality on outcome were analyzed.ResultsA total of 2,872 invasive and 1,237 in situ cases were identified. Of the invasive, 55% are transitional cell carcinoma (TCC), 21% squamous cell carcinoma (SCC), 15% adenocarcinoma or adenosquamous carcinoma, 9% unknown and other histology. Median survival time for in situ disease is 78 months, stage I (n = 231) 49 months, stage II (n = 120) 38 months, stage III (n = 91) 38 months, and stage IV excluding M1 36 months. Treatment modality was stratified into 4 groups: Surgery only (SO), surgery and radiation (SRT), radiation only (RO), and no surgery or radiation (XX). SO was used to treat the majority of patients, especially males (92%), and those with in situ (86%) or stage I (78%) disease. Four hundred ninety-nine invasive cases were identified that were M0, completely staged, and with data on treatment modality used. All of these cases were diagnosed between 2004-2008, with median follow-up of 33 months. These cases were treated as follows: SO n = 339, SRT n = 80, RO n = 32, XX n = 48. On univariate analysis, worse cause specific survival (CSS) is associated with higher stage, grade, large tumor size, adenocarcinoma histology, female sex and diagnosis before 1998. SRT patients have a higher percentage of these poor prognostic factors than SO patients, indicating a different referral pattern for adjuvant radiation therapy between these two groups. Multivariate analysis showed overall better CSS in SO versus SRT (80% vs. 48%, p = 0.007). Significantly better 5-year overall survival (OS) and CSS were seen in SO versus SRT in patients who had gross total resection (GTR) (OS: 25% vs. 0%, p = 0.022; CSS: 73% vs. 20%, p = 0.003) or with partial tumor resection (PTR) (OS: 30% vs. 13%, p = 0.033; CSS: 77% vs. 52%, p = 0.025).ConclusionsBased on available SEER data, with its inherent shortcomings, we have found no evidence that adding radiation to surgery improves OS or CSS for invasive urethral cancer. However, the magnitude of the difference in survival between SO and SRT in PTR is much smaller than for GTR. We believe that this indicates a necessity for further studies on subgroups of PTR, such as those with proximal urethral cancer, which may benefit from adjuvant radiation. Purpose/Objective(s)Urethral cancer comprises less than 1% of malignancies. Large series are not available to inform best practices. Our analysis was conducted with the intent of providing additional information about this disease. Urethral cancer comprises less than 1% of malignancies. Large series are not available to inform best practices. Our analysis was conducted with the intent of providing additional information about this disease. Materials/MethodsPatients with urethral cancer diagnosed between 1973 and 2008 were identified in the Surveillance, Epidemiology and End Results (SEER) database. The influences of demographic characteristics and treatment modality on outcome were analyzed. Patients with urethral cancer diagnosed between 1973 and 2008 were identified in the Surveillance, Epidemiology and End Results (SEER) database. The influences of demographic characteristics and treatment modality on outcome were analyzed. ResultsA total of 2,872 invasive and 1,237 in situ cases were identified. Of the invasive, 55% are transitional cell carcinoma (TCC), 21% squamous cell carcinoma (SCC), 15% adenocarcinoma or adenosquamous carcinoma, 9% unknown and other histology. Median survival time for in situ disease is 78 months, stage I (n = 231) 49 months, stage II (n = 120) 38 months, stage III (n = 91) 38 months, and stage IV excluding M1 36 months. Treatment modality was stratified into 4 groups: Surgery only (SO), surgery and radiation (SRT), radiation only (RO), and no surgery or radiation (XX). SO was used to treat the majority of patients, especially males (92%), and those with in situ (86%) or stage I (78%) disease. Four hundred ninety-nine invasive cases were identified that were M0, completely staged, and with data on treatment modality used. All of these cases were diagnosed between 2004-2008, with median follow-up of 33 months. These cases were treated as follows: SO n = 339, SRT n = 80, RO n = 32, XX n = 48. On univariate analysis, worse cause specific survival (CSS) is associated with higher stage, grade, large tumor size, adenocarcinoma histology, female sex and diagnosis before 1998. SRT patients have a higher percentage of these poor prognostic factors than SO patients, indicating a different referral pattern for adjuvant radiation therapy between these two groups. Multivariate analysis showed overall better CSS in SO versus SRT (80% vs. 48%, p = 0.007). Significantly better 5-year overall survival (OS) and CSS were seen in SO versus SRT in patients who had gross total resection (GTR) (OS: 25% vs. 0%, p = 0.022; CSS: 73% vs. 20%, p = 0.003) or with partial tumor resection (PTR) (OS: 30% vs. 13%, p = 0.033; CSS: 77% vs. 52%, p = 0.025). A total of 2,872 invasive and 1,237 in situ cases were identified. Of the invasive, 55% are transitional cell carcinoma (TCC), 21% squamous cell carcinoma (SCC), 15% adenocarcinoma or adenosquamous carcinoma, 9% unknown and other histology. Median survival time for in situ disease is 78 months, stage I (n = 231) 49 months, stage II (n = 120) 38 months, stage III (n = 91) 38 months, and stage IV excluding M1 36 months. Treatment modality was stratified into 4 groups: Surgery only (SO), surgery and radiation (SRT), radiation only (RO), and no surgery or radiation (XX). SO was used to treat the majority of patients, especially males (92%), and those with in situ (86%) or stage I (78%) disease. Four hundred ninety-nine invasive cases were identified that were M0, completely staged, and with data on treatment modality used. All of these cases were diagnosed between 2004-2008, with median follow-up of 33 months. These cases were treated as follows: SO n = 339, SRT n = 80, RO n = 32, XX n = 48. On univariate analysis, worse cause specific survival (CSS) is associated with higher stage, grade, large tumor size, adenocarcinoma histology, female sex and diagnosis before 1998. SRT patients have a higher percentage of these poor prognostic factors than SO patients, indicating a different referral pattern for adjuvant radiation therapy between these two groups. Multivariate analysis showed overall better CSS in SO versus SRT (80% vs. 48%, p = 0.007). Significantly better 5-year overall survival (OS) and CSS were seen in SO versus SRT in patients who had gross total resection (GTR) (OS: 25% vs. 0%, p = 0.022; CSS: 73% vs. 20%, p = 0.003) or with partial tumor resection (PTR) (OS: 30% vs. 13%, p = 0.033; CSS: 77% vs. 52%, p = 0.025). ConclusionsBased on available SEER data, with its inherent shortcomings, we have found no evidence that adding radiation to surgery improves OS or CSS for invasive urethral cancer. However, the magnitude of the difference in survival between SO and SRT in PTR is much smaller than for GTR. We believe that this indicates a necessity for further studies on subgroups of PTR, such as those with proximal urethral cancer, which may benefit from adjuvant radiation. Based on available SEER data, with its inherent shortcomings, we have found no evidence that adding radiation to surgery improves OS or CSS for invasive urethral cancer. However, the magnitude of the difference in survival between SO and SRT in PTR is much smaller than for GTR. We believe that this indicates a necessity for further studies on subgroups of PTR, such as those with proximal urethral cancer, which may benefit from adjuvant radiation.